Myeloid microvesicles are a marker and therapeutic target for neuroinflammation
Authors:
- Claudia VerderioCVClaudia Verderio
- Luca MuzioLMLuca Muzio
- Elena TurolaETElena Turola
- Alessandra BergamiABAlessandra Bergami
- Irene CorradiniICIrene Corradini
- Maura FrancoliniMFMaura Francolini
- Livia GarzettiLGLivia Garzetti
- Chiara MaiorinoCMChiara Maiorino
Top Cited Papers
- 24 April 2012
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 72 (4) , 610-624
Abstract
Objective: Microvesicles (MVs) have been indicated as important mediators of intercellular communication and are emerging as new biomarkers of tissue damage. Our previous data indicate that reactive microglia/macrophages release MVs in vitro. The aim of the study was to evaluate whether MVs are released by microglia/macrophages in vivo and whether their number varies in brain inflammatory conditions, such as multiple sclerosis (MS).Methods: Electron and fluorescence microscopy and flow cytometry were used to detect myeloid MVs in the cerebrospinal fluid (CSF) of healthy controls, MS patients, and rodents affected by experimental autoimmune encephalomyelitis (EAE), the animal model of MS.Results: Myeloid MVs were detected in CSF of healthy controls. In relapsing and remitting EAE mice, the concentration of myeloid MVs in the CSF was significantly increased and closely associated with disease course. Analysis of MVs in the CSF of 28 relapsing patients and 28 patients with clinical isolated syndrome from 2 independent cohorts revealed higher levels of myeloid MVs than in 13 age‐matched controls, indicating a clinical value of MVs as a companion tool to capture disease activity. Myeloid MVs were found to spread inflammatory signals both in vitro and in vivo at the site of administration; mice impaired in MV shedding were protected from EAE, suggesting a pathogenic role for MVs in the disease. Finally, FTY720, the first approved oral MS drug, significantly reduced the amount of MVs in the CSF of EAE‐treated mice.Interpretation: These findings identify myeloid MVs as a marker and therapeutic target of brain inflammation. ANN NEUROL 2012;72:610–624Keywords
This publication has 55 references indexed in Scilit:
- Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolismThe EMBO Journal, 2012
- Membrane vesicles, current state-of-the-art: emerging role of extracellular vesiclesCellular and Molecular Life Sciences, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Inhibition of Myelin Membrane Sheath Formation by Oligodendrocyte-derived Exosome-like VesiclesJournal of Biological Chemistry, 2011
- Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressantsBiochemical and Biophysical Research Communications, 2011
- MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α–PU.1 pathwayNature Medicine, 2010
- Membrane vesicles as conveyors of immune responsesNature Reviews Immunology, 2009
- Localizing central nervous system immune surveillance: Meningeal antigen‐presenting cells activate T cells during experimental autoimmune encephalomyelitisAnnals of Neurology, 2009
- Acid sphingomyelinase activity triggers microparticle release from glial cellsThe EMBO Journal, 2009
- The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammationModern Rheumatology, 2008